Short answer
Kymera Therapeutics, Inc. (KYMR) filed an 8-K current report with the SEC on August 5, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Kymera reported financial results for quarter ended June 30, 2026.
Kymera Therapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Kymera reported financial results for quarter ended June 30, 2026
- Full results and management commentary provided in Exhibit 99.1 press release
- Disclosure furnished under Item 2.02, limiting Section 18 Exchange Act liability
Item EX-99.1 · Exhibit EX-99.1
- Q2 collaboration revenue $65.0M, including $45M from Gilead and $20M Sanofi milestone payments
- BROADEN2 AD enrollment completed nearly six months early, pulling expected KT-621 data forward to year-end 2026
- KT-621 Phase 3 AD trials planned by mid-2027, creating an earlier regulatory-development catalyst
- R&D expense rose to $119.5M from $78.4M as Kymera expanded STAT6 and discovery investments
- Cash, equivalents and investments $1.5B, supporting operations into 2029 beyond multiple clinical inflection points
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Kymera Therapeutics, Inc. 8-K filings
Get the next KYMR 8-K as it lands
Follow KYMR for push alerts, or ask the research agent what this filing means.